LSD
Lysergic Acid Diethylamide
Formula: C20H25N3O
Drug class: Psychedelic
Other names: L, Acid, Lucy, Tabs
Onset of action: 30-40 minutes
Peak: 8-20 hours
LSD
LSD (lysergic acid diethylamide) is a semi-synthetic compound first developed in 1938 by Dr. Albert Hofmann at the Sandoz pharmaceutical company in Basel, Switzerland. After Dr. Hofmann first discovered its effects in 1943, LSD quickly became recognized for its possible therapeutic effects. LSD also played a significant role in the discovery of the serotonin neurotransmitter system.
Did you know?
- From the 1950s through the early 1970s, psychiatrists, therapists, and researchers administered LSD to thousands of people.
- LSD is known for its ability to catalyze spiritual or mystical experiences and to facilitate feelings of interconnection.
- MAPS-sponsored study results indicate that LSD-assisted therapy can be safely administered and justifies further research.
STUDIES
THE DROP
See what’s happening in today’s LSD news.
Red Table Talk with the Smith Family: The Miracle Treatment We Almost Couldn’t Tell You About
November 10, 2021
Summary: On a new episode of Red Table Talk, Jaden Smith, Jada Pinkett Smith, and Gammy Norris speak with author Michael Pollan, journalist Lisa Ling, oncologist Paul Song, and entrepreneur Bob Parsons …
WIRED: Big Tech’s Psychedelics Grift
November 7, 2021
Summary: WIRED investigates the growth of support for psychedelic medicine, highlighting how entrepreneurs from the technology industry are contributing to the field through philanthropic contributions …
NBC News NOW: Could Mushrooms, Molly and Acid Be the New Wave of Mental Health Care?
October 13, 2021
“The best way to create access right now is to go through the drug development process and have [psychedelic-assisted therapies] approved by the FDA,” Amy Emerson, CEO of MAPS Public Benefit …
MAPS Podcast: Episode 39 – James Oroc: The New Psychedelic Revolution
April 4, 2019
Originally appearing here. In this episode of the MAPS Podcast, James Oroc, journalist, photographer, and artist, offers his insights, opinions and experiences on topics ranging from 5-MEO DMT, the re-birth …
MAPS Podcast: Episode 28 – Lex Pelger: The Inner Workings of a Drug Writer
April 24, 2018
Originally appearing here. The inner workings of a drug writer as he shares his perspective, spirit and mind. Lex Pelger – the blazingly prolific writer, podcaster, traveling salon MC and psychedelic …
MAPS Podcast: Episode 27 – Dieter Hagenbach, Albert Hofmann, and His LSD
April 7, 2018
Originally appearing here. April 2018 marks the 75th anniversary of the first experiences with LSD that Dr. Hofmann embarked on in Basel, Switzerland. It’s the perfect occasion to revisit this talk …
MAPS Podcast: Episode 18 – Dr. Ben Sessa
October 25, 2017
Originally appearing here.The State of Psychedelic Therapy, Culture and Policy in the UK and Beyond with Dr. Ben Sessa Ben beams in via cyberspace for an original episode of The MAPS Podcast. Ben’s …
MAPS Podcast: Episode 17 – Brain Imaging with Psilocybin and MDMA – Dr. Robin Carhart-Harris
September 29, 2017
Originally appearing here.Have you wondered what happens on a neuro-scientific and physiological level when phsychedelics enter your body? That question has been at the root of the psychedelic experience …
MAPS Podcast: Episode 8 – LSD and Neuroscience – David E. Nichols
May 17, 2017
Originally appearing here.Taken from the Psychedelic Science ’13 conference this epic talk from Heffter Research Institute Founder, David E. Nichols, explores the depths of the brains relationship …
MAPS Podcast: Episode 1 – Scientific Problem Solving with Psychedelics – James Fadiman, Ph.D.
March 18, 2017
Originally appearing here.James will describe how to best use psychoactive materials for enhanced problem solving, a poorly understood and under-researched area. However, there are established methods …
Swiss Study: International Federation of Psychotherapy Congress in Lucern, Switzerland Hosts Mithoefers, Gasser, Oehen, and Passie
June 21, 2010
From June 16-19, the International Federation of Psychotherapy convened a Congress in Lucerne, Switzerland. As a sign of the growing acceptance of psychedelic psychotherapy research, this mainstream psychotherapy …
Switzerland Study: One-Year Follow-Up Study Proceeds
May 23, 2010
The Swiss MDMA/PTSD study, led by Principal Investigator Peter Oehen M.D. with co-investigator Verena Widmer, R.N., has completed all experimental treatments and is currently in the one-year follow-up …